Haderski, G. J., Kandar, B. M., Brackett, C. M., Toshkov, I. M., Johnson, C. P., Paszkiewicz, G. M., . . . Burdelya, L. G. (2020). TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. PLoS One.
Chicago-tyylinen lähdeviittausHaderski, Gary J., et al. "TLR5 Agonist Entolimod Reduces the Adverse Toxicity of TNF While Preserving Its Antitumor Effects." PLoS One 2020.
MLA-viiteHaderski, Gary J., et al. "TLR5 Agonist Entolimod Reduces the Adverse Toxicity of TNF While Preserving Its Antitumor Effects." PLoS One 2020.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.